TITLE

Viagra for the Thighs?

AUTHOR(S)
Lemonick, Michael D.; Park, Alice
PUB. DATE
May 1999
SOURCE
Time;5/10/1999, Vol. 153 Issue 18, p72
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Announces the release of the drug orlistat for weight loss in the United States. Drug to be manufactured by Hoffman-LaRoche as Xenical; Possible side effects; How the drug works; Importance of changing one's eating habits and exercising; Critics of putting the drug on the market.
ACCESSION #
1796918

 

Related Articles

  • Viagra for the Thighs? Lemonick, Michael D.; Park, Alice // Time International (South Pacific Edition);05/10/1999, Issue 19, p58 

    Announces the release of the drug orlistat for weight loss in the United States. Drug to be manufactured by Hoffman-LaRoche as Xenical; Possible side effects; How the drug works; Importance of changing one's eating habits and exercising; Critics of putting the drug on the market.

  • Finally, the Free Lunch? Springen, Karen // Newsweek;2/1/1999, Vol. 133 Issue 5, p57 

    Reports on orlistat, a drug that blocks the absorption of dietary fat developed by Hoffman-La Roche and under consideration for approval by the United States Food and Drug Administration (FDA) as of January 1999. Details of the study of the obesity drug, and comments from study author John...

  • New fat blocker?  // Joe Weider's Muscle & Fitness;Apr94, Vol. 55 Issue 4, p25 

    Reports on the development of the drug orlistat by Hoffman-La Roche for keeping some consumed fat from being broken down and used by the body. Recommended for the seriously overweight; Testing for the effectivity of orlistat.

  • Xenical's marketing appeal: Obesity is not in the mind, it is in the gut.  // Medical Marketing & Media;Jun99, Vol. 34 Issue 6, p18 

    Focuses on the marketing plans for the weight-loss substance called Orlistat from Hoffmann-La Roche Inc. Action of the drug on blocking dietary fat.

  • Fighting fat.  // Drug Topics;6/2/97, Vol. 141 Issue 11, p30 

    Reports on the US Food and Drug Administration's approval of Hoffmann-La Roche's anti-obesity drug Xenical.

  • New `fat blocking' anti-obesity drug on the horizon.  // Drug Store News;6/16/97, Vol. 19 Issue 10, Chain Pharmacy p6 

    Reports on the recommendation by the Endocrinology and Metabolic Drug Advisory Committee of the US Food and Drug Administration of the approval of Hoffmann-La Roche Inc.'s Xenical antiobesity drug.

  • Roche resubmits Xenical NDA in face of phen-fen legal action.  // Medical Marketing & Media;Dec97, Vol. 32 Issue 12, p24 

    Reports that Hoffmann-La Roche has resubmitted its new drug application for the anti-obesity drug Xenical or orlistat at the US Food and Drug Administration. Mechanism of action of Xenical; Recall of the anti-obesity drugs Pondimin and Redux.

  • Xenical ad campaign planned.  // Medical Marketing & Media;Mar2001, Vol. 36 Issue 3, p24 

    Reports on the plans of Roche Laboratories to schedule the follow-up advertising campaign for Xenical. Inclusion of informational advertisements in the introductory campaign; Emphasis of the campaign on the health problem associated with overweight; Presentation on the side effects of the drug.

  • Orlistat approved.  // Healthy Weight Journal;Sep/Oct1999, Vol. 13 Issue 5, p66 

    Reports on the approval of the drug orlistat from Roche Laboratories for the treatment of obesity. Efficacy of the drug; Side effects of the drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics